ArticleMedicine2026
Trends and disparities in the burden of autoimmune diseases in China and globally: A comparative analysis based on the Global Burden of Disease Study 2021.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to quantify long-term trends and burdens of 5 autoimmune diseases in China and globally from 1990 to 2021 using Global Burden of Disease 2021 data and identify drivers of change to guide prevention and health planning. Using Global Burden of Disease 2021 data, we analyzed type 1 diabetes mellitus (T1DM), inflammatory bowel disease (IBD), multiple sclerosis (MS), psoriasis (PS), and rheumatoid arthritis (RA) in China and worldwide from 1990 to 2021. We assessed age-standardized prevalence, disability-adjusted life years (DALYs), and temporal trends via joinpoint regression, and decomposed DALY changes into contributions from population growth, aging, and epidemiological transition. In 2021, global age-standardized prevalence (per 1,00,000) was highest for PS (515.95), followed by T1DM (238.19), RA (208.90), IBD (44.88), and MS (22.17). In China, RA (240.70) exceeded global levels, PS (474.02) was similar, and the other diseases were lower. All 5 autoimmune diseases showed increasing trends in China (IBD 1.62%, MS 1.21%, PS 0.88%, RA 0.51%, T1DM 1.15%), with growth rates surpassing global averages. DALY decomposition showed declines in IBD (AAPC = -2.86%) and T1DM (AAPC = -1.86%) driven by epidemiological improvements; increases in MS (AAPC = 0.95%) and PS (AAPC = 0.88%) driven by worsening patterns and aging; and stable RA burden (AAPC = -0.02%) mainly influenced by population growth and aging. Over 3 decades, autoimmune disease prevalence in China rose substantially, narrowing gaps with high-income regions. Declines in DALYs for IBD, T1DM, and RA reflect improved detection and care, while rising DALYs for MS and PS highlight the need for precision prevention, early intervention, and equitable resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.